Secondary resistance toward ALK inhibitors is a frequent observation in NSCLC patients and is also seen in neuroblastoma patients, and sometimes the switch to an alternative ALK inhibitor becomes necessary [91]. This evidence concerns the gene ALK and non-small cell lung carcinoma.